Transcode Therapeutics, Inc.
RNAZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829635
No open-market purchases or sales by Transcode Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $208.1K in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Transcode Therapeutics, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 11 | 13 | +2 |
| Shares | 560.1K | 643.4K | +83.3K (+14.9%) |
| Value | $281.6K | $105.4K | −$176.2K (−62.6%) |
New holders (7)
Institutions that held Transcode Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 281,908 | $46.5K | 0.00% |
| Renaissance Technologies LLC | 187,400 | $31.0K | 0.00% |
| Geode Capital Management, LLC | 52,232 | $8.61K | 0.00% |
| Captrust Financial Advisors | 50,000 | $8.24K | 0.00% |
| Susquehanna International Group, LLP | 10,995 | $1.81K | 0.00% |
| XTX Topco Ltd | 10,740 | $1.77K | 0.00% |
| Bank of America Corp | 1,621 | $266 | 0.00% |
Sold out (5)
Institutions that held Transcode Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Sabby Management, LLC | 250,309 | $125.8K |
| Tang Capital Management LLC | 84,010 | $42.2K |
| Virtu Financial LLC | 31,347 | $16.0K |
| Two Sigma Investments, LP | 16,153 | $8.12K |
| Warberg Asset Management LLC | 10,000 | $5.03K |